Pacira BioSciences Inc.

2 months ago · zacks.com

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

2 months ago · seekingalpha.com

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Pacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.74 per share a year ago.

2 months ago · globenewswire.com

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif.

2 months ago · globenewswire.com

— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — BRISBANE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has successfully transitioned PCRX-201 (enekinragene inzadenovec), its investigational locally administered gene therapy for osteoarthritis of the knee, to a U.S.-based scalable commercial manufacturing process intended to support future registrational development and commercialization.

2 months ago · globenewswire.com

BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after the close of the U.S. markets on Tuesday August 4, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

5 months ago · globenewswire.com

SASKATOON, Saskatchewan, May 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX), a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy ownership, is pleased to announce the completion of its acquisition from an arm's length vendor (the “Vendor”) of the prescription files, patient records and related operational data (collectively, the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp's existing PharmaChoice-bannered pharmacies in Western Canada (the “Acquisition”). The purchase price for the Acquisition was $300,000, subject to customary adjustments, and was satisfied with cash on hand. No finder's fees were payable in connection with the Acquisition.

5 months ago · zacks.com

PCRX Q1 earnings miss estimates as rising costs weigh on profit, but revenues top expectations on Exparel demand and growth from Zilretta and iovera.

5 months ago · seekingalpha.com

Pacira BioSciences, Inc. (PCRX) Q1 2026 Earnings Call Transcript

5 months ago · zacks.com

Pacira (PCRX) came out with quarterly earnings of $0.6 per share, missing the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.62 per share a year ago.